{"id":"zolendronic-acid","safety":{"commonSideEffects":[{"rate":null,"effect":"Renal impairment"},{"rate":null,"effect":"Osteonecrosis of the jaw"},{"rate":null,"effect":"Atypical femoral fractures"},{"rate":"30-40","effect":"Fever"},{"rate":"20-30","effect":"Myalgia/arthralgia"},{"rate":"10-20","effect":"Nausea"}]},"_chembl":{"chemblId":"CHEMBL924","moleculeType":"Small molecule","molecularWeight":"272.09"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"As a bisphosphonate, zoledronic acid binds to hydroxyapatite in bone and is taken up by osteoclasts, where it inhibits farnesyl pyrophosphate synthase, disrupting protein prenylation and leading to osteoclast apoptosis. This reduces bone turnover and resorption, making it effective for conditions characterized by excessive bone loss or osteolytic lesions.","oneSentence":"Zoledronic acid inhibits osteoclast-mediated bone resorption by blocking farnesyl pyrophosphate synthase in the mevalonate pathway.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:39:45.825Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypercalcemia of malignancy"},{"name":"Bone metastases in solid tumors and multiple myeloma"},{"name":"Osteoporosis prevention in patients receiving aromatase inhibitors for breast cancer"}]},"trialDetails":[{"nctId":"NCT07056478","phase":"PHASE3","title":"RANKL Inhibition to Combat Sarcopenia in Hip Fracture Patients","status":"NOT_YET_RECRUITING","sponsor":"Prince of Wales Hospital, Shatin, Hong Kong","startDate":"2026-01-01","conditions":"Sarcopenia in Elderly","enrollment":130},{"nctId":"NCT06643780","phase":"PHASE4","title":"RANK-ligand Inhibition to Combat Sarcopenia with Underlying Osteoporosis","status":"RECRUITING","sponsor":"Prince of Wales Hospital, Shatin, Hong Kong","startDate":"2024-04-09","conditions":"Sarcopenia in Elderly","enrollment":120},{"nctId":"NCT01679080","phase":"PHASE2","title":"The Effect of Treatment With Teriparatide and Zoledronic Acid in Patients With Osteogenesis Imperfecta","status":"TERMINATED","sponsor":"University of Aarhus","startDate":"2012-11","conditions":"Osteogenesis Imperfecta","enrollment":9},{"nctId":"NCT04115397","phase":"PHASE4","title":"Bisphosphonates for the Treatment of Seropositive Musculoskeletal Complaints","status":"UNKNOWN","sponsor":"Karolinska Institutet","startDate":"2020-01","conditions":"Seropositive Muskuloskeletal Complaints","enrollment":80},{"nctId":"NCT01656512","phase":"PHASE3","title":"Zometa Study in Pediatric Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"Children's Cancer Hospital Egypt 57357","startDate":"2011-10","conditions":"Osteoporosis","enrollment":95},{"nctId":"NCT00375752","phase":"PHASE4","title":"Efficacy and Safety of Letrozole vs. Letrozole Plus Zoledronic Acid as Endocrine Therapy Before Surgery in Postmenopausal Patients With Breast Cancer","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2006-06-01","conditions":"Breast Neoplasms","enrollment":168},{"nctId":"NCT01472146","phase":"PHASE2","title":"ZoNantax - Zolendronic Acid as Neoadjuvant Therapy Plus Anthracycline and Taxane in Locally Advanced Breast Cancer","status":"COMPLETED","sponsor":"Susanne Crocamo","startDate":"2011-10","conditions":"Breast Cancer, Breast Disease, Neoplasms","enrollment":58},{"nctId":"NCT00559897","phase":"PHASE2","title":"Zoledronic Acid and Positron Emission Tomography in Treating Patients With Advanced Non-Small Cell Lung Cancer","status":"TERMINATED","sponsor":"Barbara Ann Karmanos Cancer Institute","startDate":"2008-03","conditions":"Lung Cancer, Metastatic Cancer","enrollment":6},{"nctId":"NCT00326820","phase":"PHASE3","title":"Ibandronate or Zoledronate in Treating Patients With Newly Diagnosed Bone Metastases From Breast Cancer","status":"UNKNOWN","sponsor":"Wales Cancer Trials Unit","startDate":"2006-01","conditions":"Breast Cancer, Hypercalcemia of Malignancy, Metastatic Cancer","enrollment":1404},{"nctId":"NCT01572545","phase":"NA","title":"Comparative Effect of Zoledronic Acid Versus Denosumab on Serum Sclerostin of Postmenopausal Women With Low Bone Mass","status":"COMPLETED","sponsor":"Aristotle University Of Thessaloniki","startDate":"2012-04","conditions":"Postmenopausal Osteoporosis","enrollment":91},{"nctId":"NCT00432458","phase":"PHASE3","title":"Zoledronate With or Without Thalidomide in Treating Patients With Early Stage Multiple Myeloma","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2003-07","conditions":"Multiple Myeloma and Plasma Cell Neoplasm","enrollment":68},{"nctId":"NCT00171340","phase":"PHASE3","title":"Zoledronic Acid in the Prevention of Cancer Treatment Related Bone Loss in Postmenopausal Women Receiving Letrozole for Breast Cancer.","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2003-05","conditions":"Bone Loss, Breast Cancer","enrollment":1065},{"nctId":"NCT00639392","phase":"PHASE1, PHASE2","title":"Phase 1 Study of Zoledronic Acid in Sickle Cell Disease","status":"WITHDRAWN","sponsor":"Virginia Commonwealth University","startDate":"2007-06","conditions":"Sickle Cell Disease","enrollment":""}],"_emaApprovals":[],"_faersSignals":[{"count":5,"reaction":"DECREASED APPETITE"},{"count":4,"reaction":"ANAEMIA"},{"count":4,"reaction":"ASTHENIA"},{"count":3,"reaction":"NEUTROPENIA"},{"count":3,"reaction":"PYREXIA"},{"count":3,"reaction":"RASH"},{"count":3,"reaction":"RENAL FAILURE ACUTE"},{"count":2,"reaction":"BACK PAIN"},{"count":2,"reaction":"BLOOD PRESSURE DECREASED"},{"count":2,"reaction":"COUGH"}],"_approvalHistory":[],"publicationCount":82,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Zoledronate","bisphosphonates"],"phase":"marketed","status":"active","brandName":"Zolendronic Acid","genericName":"Zolendronic Acid","companyName":"Wales Cancer Trials Unit","companyId":"wales-cancer-trials-unit","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Zoledronic Acid is a small molecule used in the treatment of various conditions, including Postmenopausal Osteoporosis, Breast Cancer, Hypercalcemia of Malignancy, and Metastatic Cancer. It has been studied in clinical trials as a potential treatment for Sickle Cell Disease, although one such trial was withdrawn due to unknown reasons.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}